Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Finance

GSK pitches new growth to investors post consumer healthcare split

June 23, 2021 9:34 PM UTC

GSK is hoping a return to growth, albeit at a 3% annualized rate through 2031, is enough to satiate investors who will see their dividend slashed by 31% following the split of GSK’s biopharma and consumer healthcare businesses next year.

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) spelled out its plans for the split on Wednesday, confirming it’s going ahead with the breakup in mid-2022, and signaled the potential for an uptick in BD activities, including bolt-on deals...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Glaxosmithkline plc